Stonepine Capital Management LLC Lowers Holdings in ADMA Biologics Inc $ADMA

Key Points

• Stonepine Capital Management LLC reduced its stake in ADMA Biologics by 34.7%, now holding 810,000 shares, which represents 15.4% of their overall portfolio.
• Brokerages have had mixed opinions on ADMA Biologics; while Wall Street Zen downgraded the stock to a "sell," Raymond James Financial raised its price target and rated it a "strong buy."
• Insider sales included Director Steve Elms selling 194,749 shares, a 69.04% decrease in his position, highlighting activity among corporate insiders amidst stock fluctuations.

Stonepine Capital Management LLC cut its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 34.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 810,000 shares of the biotechnology company's stock after selling 431,032 shares during the quarter. ADMA Biologics comprises approximately 15.4% of Stonepine Capital Management LLC's holdings, making the stock its largest position. Stonepine Capital Management LLC owned about 0.34% of ADMA Biologics worth $16,070,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC lifted its stake in ADMA Biologics by 100.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 89,844 shares of the biotechnology company's stock valued at $1,783,000 after acquiring an additional 44,957 shares during the last quarter. Jump Financial LLC lifted its stake in ADMA Biologics by 1,420.0% in the first quarter. Jump Financial LLC now owns 357,256 shares of the biotechnology company's stock valued at $7,088,000 after acquiring an additional 333,752 shares during the last quarter. SVB Wealth LLC acquired a new stake in ADMA Biologics in the first quarter valued at approximately $35,000. Smartleaf Asset Management LLC lifted its stake in ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 1,493 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP lifted its stake in ADMA Biologics by 53.3% in the first quarter. Advantage Alpha Capital Partners LP now owns 106,075 shares of the biotechnology company's stock valued at $2,105,000 after acquiring an additional 36,893 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Steve Elms sold 194,749 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 455,621 shares of company stock worth $9,461,633. 3.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $27.67.

ADMA Biologics Stock Performance

ADMA stock traded up $0.15 on Wednesday, reaching $17.25. 3,740,356 shares of the company were exchanged, compared to its average volume of 3,351,694. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The stock's fifty day moving average price is $17.79 and its 200 day moving average price is $18.88. The firm has a market capitalization of $4.12 billion, a PE ratio of 29.48 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the previous year, the firm posted $0.13 earnings per share. ADMA Biologics's revenue was up 13.8% compared to the same quarter last year. On average, research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.